To The Moon

$SQQQ 20250718 30.0 CALL$ I closed $SQQQ 20250718 30.0 CALL$  ,>91% profits. With only $0.03 worth of protection. Not worth the hedge. Take off the hedge and monitor how it goes >91% profits. With only $0.03 worth of protection. Not worth the hedge. Take off the hedge and monitor how it goes 

$SMMT 20250711 22.0 PUT$ SMMT：生物醫療領域的潛力新貴，向巔峯進擊 在競爭激烈的生物醫療領域，SMMT正以驚人的速度崛起，其展現出的潛力猶如一座蘊藏無盡價值的寶藏，吸引着全球投資者與行業目光。 從研發實力來看，SMMT聚焦癌症治療領域，擁有一支頂尖科研團隊。他們憑藉對前沿技術的深刻理解與探索熱情，不斷突破創新。以明星產品ivonescimab爲例，這款從中國藥企引進授權的肺癌治療藥物，在晚期臨牀試驗中取得了令人矚目的成績。其卓越的療效不僅爲無數癌症患者帶來了新的希望，也彰顯出SMMT在藥物研發方向上精準的前瞻性。憑藉此藥物，SMMT成功在生物醫療研發賽道上佔據了重要一席，更爲後續更多創新藥物的研發積累了寶貴經驗與強大的技術背書。 商業合作層面，SMMT的發展潛力同樣不容小覷。近期，與行業巨頭阿斯利康的潛在合作傳聞，更是將其推向了輿論焦點。據彭博社報道，雙方就ivonescimab的合作展開談判，潛在交易價值高達150億美元。如此鉅額的合作意向，不僅是對SMMT現有成果的高度認可，更預示着其未來廣闊的商業前景。若合作達成，藉助阿斯利康龐大的市場渠道、豐富的商業化經驗以及雄厚的資金支持，SMMT的產品將能夠快速觸達全球患者，實現商業價值的爆發式增長。同時，此次合作也將爲SMMT帶來更多資源，助力其在後續研發、拓展新治療領域等方面持續發力。 在市場佈局上，SMMT也有着清晰而長遠的規劃。儘管目前處於臨牀階段，但憑藉創新藥物和潛在的重磅合作，它已經在資本市場引起強烈反響。其股價的大幅飆升，正是市場對其潛力的直接反饋。隨着全球對癌症治療需求的持續增長，以及生物醫療行業的蓬勃發展，SMMT有望藉助自身優勢，逐步擴大市場份額，

$Xiaomi Corp.(XIACY)$ Buying the dip from the last rally. Bullish in the short term but will be monitoring prices closely given the current market conditions.

$Direxion Daily Semiconductors Bull 3x Shares(SOXL)$ As an investor who closely follows technology trends and structural shifts in the global economy, my decision to invest in SOXL was neither impulsive nor speculative. It was a conviction-based move grounded in long-term optimism about the semiconductor industry and a clear strategy to manage risk through volatility. Semiconductors are the foundation of every major technological breakthrough today from artificial intelligence and cloud computing to autonomous vehicles, 5G, and robotics. In my view, they are not just part of a cyclical sector anymore; they represent a long-term, structural growth story. The demand for more computing power, faster connectivity, and smarter systems only continu

The Buffet of Opportunities: Why You Can’t Eat It All One of the key lessons I’ve learned over time is this: During market downturns, opportunities multiply—but your capital doesn’t. For example, in a recent market dip, we saw several high-quality companies trading at deeply attractive valuations. April alone gave us what looked like a buffet of blue-chip bargains. But here’s the challenge that every investor—retail or institutional—must face: capital constraints. When you see multiple great opportunities at once, the natural instinct is to want to buy everything. But that’s exactly where most mistakes happen. ⸻ The Capital Allocation Trap Just like a buffet, the market may serve 20 amazing dishes. But if you try to sample all of them, you end up bloated, exhausted, and likely regretting t

$TENCENT(00700)$ the tech giant, is back on the rise! The current stock price stands at HKD 503.50, up steadily by about 1% from the cost price of HKD 498.472, yielding a profit of HKD 1,005.63. With the regular issuance of game licenses and accelerated commercialization of Video Accounts, the company’s core businesses are warming up. Coupled with innovative initiatives like AI large models, Tencent’s long-term growth momentum remains strong and promising.

$CHINA LIT(00772)$ , a leading brand in men's apparel, is showing steady upward momentum! The current stock price is HKD 29.650, up 1.3% from the cost price of HKD 29.265, resulting in a gain of HKD 1,538.78. The company has made remarkable progress through product rejuvenation and channel optimization. With e-commerce sales during the 618 shopping festival soaring over 30% year-on-year, the traditional peak season in the second half of the year looks promising.

$HUTCHMED(00013)$ a leader in innovative pharmaceuticals, continues to break new ground! The current stock price is HKD 24.75, up 1.7% from the cost price of HKD 24.338, resulting in a paper gain of HKD 3,708.52! The company’s oncology pipeline reports frequent positive clinical results, overseas licensing and collaborations steadily advance, and its internationalization strategy for innovative drugs has entered a fruitful stage, fully unlocking long-term growth potential!

$ProShares UltraPro Short Russell 2000(SRTY)$ strategy paid off handsomely! The current price has climbed to $16.24 from my entry at $15.78, marking a 2.9% gain and $320.70 in profit. With small-cap stocks still under pressure amid ongoing recession fears, this 3x inverse ETF served as a perfect hedge. The Fed’s recent hawkish tone further reinforces the value of this position. I’m holding on for now, waiting to see if the upcoming nonfarm payroll data will confirm the market’s recession narrative.

$Constellation Energy Corp(CEG)$ showed steady gains. The current price of $319.00 reflects a 2.3% increase from my cost basis of $311.76, generating $325.97 in profits. As America's largest carbon-free energy provider, the company benefits from pro-nuclear policies and rising power price expectations, with long-term PPAs ensuring stable cash flows.

$Sirius XM(SIRI)$ defied the market with a 1.5% gain to $23.62, earning $430.82 over the $23.27 cost. Strong in-car subscriber loyalty, growing ties with Tesla, and exclusive sports rights strengthen its moat. A 3.2% dividend yield adds to its investment appeal.

$IONQ Inc.(IONQ)$ is absolutely crushing it this round! The stock has surged to $45.24 from my entry at $43.61 — that’s a 3.7% gain and $577.99 in unrealized profit. I’m grinning like a quantum physicist right now! As the global race for quantum supremacy heats up, IONQ’s ion trap technology has earned Google’s backing, giving it serious technical clout. Honestly, it’s hard to say where the ceiling is for this company — the sky might not be the limit!

$Palantir Technologies Inc.(PLTR)$ , the undisputed king of big data, has soared to a new high again! The current share price stands at $138.80, up 2.6% from the $135.28 entry point, locking in a solid $703.02 in gains. As a leading AI-driven data analytics powerhouse, Palantir is seeing sustained growth in government contracts and stronger-than-expected momentum from commercial clients. Its AIP platform is sparking a new wave of enterprise AI adoption. With earnings season ahead, confidence remains high — holding firm for what’s next!

$JinkoSolar(JKS)$ is leading the charge in the solar sector today! The stock has steadily climbed to $23.83 from our entry at $23.21, delivering a solid 2.7% gain and a profit of $803.45. Confidence is high — holding firm and adding more in anticipation of the next major rally!

$Oklo Inc.(OKLO)$ lit up the market today—what a shining star in the nuclear sector! The stock surged to $56.80 from a cost basis of $52.53, posting a strong 7.7% gain and raking in a cool $805.02 profit! As a front-runner in next-generation nuclear technology, Oklo’s focus on small modular reactors (SMRs) has earned strong support from the U.S. Department of Energy. With policy tailwinds and technological breakthroughs fueling momentum, the stock broke out of its range and soared to a new high. Absolutely electrifying!